Clinical Trial

Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

Study acronym: GLIOTARG
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
GLIOTARG trial is a large single-center observational cohort study designed to investigate chemotherapy and targeted therapy outcomes in recurrent malignant gliomas. The study includes patients with molecularly confirmed diagnoses according to the World Health Organization (WHO) 2021 classification of Central Nervous System (CNS) tumors: glioblastomas (IDH-wildtype, WHO grade 4), astrocytomas (IDH-mutant, WHO grade 3-4), and pleomorphic xanthoastrocytomas (WHO grade 2-3).
Trial Details
NCT Number NCT07448480
Lead Sponsor Blokhin's Russian Cancer Research Center
Conditions Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, Pleomorphic Xanthoastrocytoma
Enrollment 1,000 participants
Start Date 2026-02-01
Primary Completion 2027-10-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-04